Orforglipron
Also known as: LY3502970, Oral non-peptide GLP-1 receptor agonist
Orforglipron is a catalog-expanded glp1 entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, explicit_target_list, local_seed, project_target. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Phase 3 ATTAIN-1 obesity trial uses dose-escalation up to 36 mg daily. Oral, non-peptide structure unlike injectable GLP-1 analogs.
No published cycle data available.
Unlike oral semaglutide, no fasting/water-volume restrictions because the molecule is not a peptide.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Diarrhea
- • Vomiting
- • Constipation
- • Decreased appetite
Serious risks
- • Pancreatitis risk (class effect)
- • Thyroid C-cell tumor risk (class effect, animal data)
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited human data
- Not a peptide — small-molecule oral GLP-1 agonist with predictable absorption
- Not yet approved — investigational only as of 2026
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.